Putting patients on the lipid-lowering drug actually contributed to hepatic and renal failure, Jonathon D. Truwit, MD, of the Medical College of Wisconsin in Milwaukee, and colleagues found in the ARDS Clinical Trials Network study.
In the STATCOPE trial, simvastatin (Zocor) didn't prevent COPD exacerbations compared with placebo (1.36 versus 1.39 mean per person-year, P=0.54) or delay them (median 223 versus 231 days to first exacerbation, P=0.34), Gerard Criner, MD, of Temple University in Philadelphia, reported at the meeting.
Both National Heart, Lung, and Blood Institute-sponsored trials were reported at a late-breaking clinical trials session here at the American Thoracic Society meeting and released simultaneously online in the New England Journal of Medicine.
Read the complete article here. See also NEJM article here.